Sana Biotechnology Inc (SANA) Stock Price, Quote & News

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modi...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 701 7914

Website: www.sana.com

Address:

188 East Blaine Street, Suite 400, Seattle, United States

rubraquercus Sep. 12 at 12:16 PM

$SANA Love the stock and hope it cures me someday but this bump up smells like a raise $

2 · Reply

CelestialIronMan Sep. 12 at 1:37 AM

$SANA you were stupid enough to think China was going to be allowed to lead the US in medicine? If we ban it, it never happened…

1 · Reply

OliveGardenCPA Sep. 11 at 10:23 PM

$SANA BACK TO $35.09

1 · Reply

Lowboy9191 Sep. 11 at 7:35 PM

$SANA i like it!!!

0 · Reply

ItsAllAboutBeingFirst Sep. 11 at 6:13 PM

$LCTX $SANA $GOSS all.....

0 · Reply

LunarPixel87 Sep. 11 at 6:05 PM

$SANA I have zero sympathy for any shorts. Shorting Sana is like betting against humanity. What they've demonstrated works in humans is beyond remarkable. World changing.

0 · Reply

StockosaurusRex Sep. 11 at 6:00 PM

$SANA I don't know, the volume today is not even half the daily and we are closing in on the day. This seems like natural movement. Maybe those conferences they are doing have got them excited.

0 · Reply

cta7978 Sep. 11 at 5:58 PM

$SANA This is feeling a bit squeezy?

0 · Reply

_www_larval_com_ Sep. 11 at 4:42 PM

$SANA just popped 4% higher to 9% (~2Mv) a few minutes ago, 09/19 options, follow for more volatility.

0 · Reply

cta7978 Sep. 11 at 4:36 PM

$SANA Signs of life

0 · Reply

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:42 AM EDT - 7 days ago

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 10:03 PM EDT - 10 days ago

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 15 days ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX IQV MRNA

Aug 26, 2025, 4:05 PM EDT - 17 days ago

Sana Biotechnology to Present at September 2025 Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 23 days ago

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 8, 2025, 2:58 PM EDT - 5 weeks ago

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Aug 6, 2025, 11:24 PM EDT - 5 weeks ago

Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 4:38 PM EDT - 5 weeks ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 6, 2025, 7:00 AM EDT - 5 weeks ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

MCRB

Aug 4, 2025, 11:35 AM EDT - 5 weeks ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Jun 23, 2025, 10:05 AM EDT - 2 months ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jun 23, 2025, 7:39 AM EDT - 2 months ago

Two Biotech Stocks Poised For Big Moves On Monday

LCTX

Jun 9, 2025, 4:05 PM EDT - 3 months ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

May 28, 2025, 4:05 PM EDT - 3 months ago

Sana Biotechnology to Present at June 2025 Investor Conferences

May 19, 2025, 3:10 PM EDT - 4 months ago

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

May 19, 2025, 11:57 AM EDT - 4 months ago

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

May 14, 2025, 2:50 PM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 12, 2025, 4:05 PM EDT - 4 months ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

May 8, 2025, 5:45 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

Apr 19, 2025, 8:10 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

Mar 24, 2025, 11:45 PM EDT - 6 months ago

Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421

Mar 17, 2025, 4:05 PM EDT - 6 months ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 4:05 PM EST - 7 months ago

Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference

Jan 8, 2025, 4:05 PM EST - 8 months ago

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 10:30 AM EST - 8 months ago

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Jan 8, 2025, 9:27 AM EST - 8 months ago

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

Jan 8, 2025, 7:25 AM EST - 8 months ago

This Biotech Stock Just Soared 240%. Why It Can Go Higher.

rubraquercus Sep. 12 at 12:16 PM

$SANA Love the stock and hope it cures me someday but this bump up smells like a raise $

2 · Reply

CelestialIronMan Sep. 12 at 1:37 AM

$SANA you were stupid enough to think China was going to be allowed to lead the US in medicine? If we ban it, it never happened…

1 · Reply

OliveGardenCPA Sep. 11 at 10:23 PM

$SANA BACK TO $35.09

1 · Reply

Lowboy9191 Sep. 11 at 7:35 PM

$SANA i like it!!!

0 · Reply

ItsAllAboutBeingFirst Sep. 11 at 6:13 PM

$LCTX $SANA $GOSS all.....

0 · Reply

LunarPixel87 Sep. 11 at 6:05 PM

$SANA I have zero sympathy for any shorts. Shorting Sana is like betting against humanity. What they've demonstrated works in humans is beyond remarkable. World changing.

0 · Reply

StockosaurusRex Sep. 11 at 6:00 PM

$SANA I don't know, the volume today is not even half the daily and we are closing in on the day. This seems like natural movement. Maybe those conferences they are doing have got them excited.

0 · Reply

cta7978 Sep. 11 at 5:58 PM

$SANA This is feeling a bit squeezy?

0 · Reply

_www_larval_com_ Sep. 11 at 4:42 PM

$SANA just popped 4% higher to 9% (~2Mv) a few minutes ago, 09/19 options, follow for more volatility.

0 · Reply

cta7978 Sep. 11 at 4:36 PM

$SANA Signs of life

0 · Reply

JerryMalone32 Sep. 10 at 5:00 PM

$SANA The most interesting comment made by Steve (to me) was at the 27-minute mark of the Morgan Stanley conference. Where he discussed options for fusogen platform. One of the options he mentioned was a spin-out where $SANA would retain a majority interest. And then possibly buy it back (or sell it) after human data. My bet is they do spin it out.

2 · Reply

LunarPixel87 Sep. 10 at 10:43 AM

$SANA no source... useless. Anything I've seen from China required immunosuppression. Also, what they described isn't a first. Vertex (an American company) has already shown stem cell derived islets enable insulin independence in humans, problem being that they required immunosuppression, the problem which Sana has solved. Almost seems like there's a Chinese smear campaign to diminish Sana's achievement or something. Really annoying. First protocols for making stem cell derived islets came from US labs by the way. First islets and human cells to survive long-term term without immunosuppression was demonstrated by $SANA, an American company. Nothing can change that, it's history. $SANA patents will take priority even if China copies them. Pretty tired of hearing China this and China that especially with no sources and inaccurate statements.

3 · Reply

Olivia_Love Sep. 10 at 7:18 AM

$SANA what SANA?

2 · Reply

jaykalope Sep. 9 at 5:37 PM

$SANA short presentation today just covering the science in ways we are already familiar with. No discussion about finance at all. The one thing that is new-ish is just the 26 week update on the patient who received the HIP islets- still no sign of immune rejection or change in islet function.

2 · Reply

mirko_papuga Sep. 9 at 4:04 AM

$SANA Market is a lot bigger than anyone realized: https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness

2 · Reply

BriOnH Sep. 8 at 9:19 PM

$SANA In today's Morgan Stanley 23rd Annual Global Healthcare Conference presentation Harr made it 100% crystal clear: Money is the issue. It really boggles my mind how there's investors here that are in denial of not only the lack of funds they have moving forward, but the denial of how hard it is to get money, to get their most valuable asset at this time, sc451, to market, ON TOP OF having to kill other SC's because of funds. Another answer that was finally, completely, explained was the choice of Sana not to use the Edmonton Protocol, that is the use of the portal vein for delivery of the islets/sc451. Short answer it requires radiological intervention, which makes it less scalable, and has serious side effects, (not mentioned from today but known) like thrombosis and inflammation. This is the 3rd of 4 healthcare conferences in September for Sana, with tomorrow being the 4th. I think the information has been very forward moving and very enlightening.

3 · Reply

gobio Sep. 8 at 3:40 PM

$SANA https://www.nature.com/articles/d41586-025-02802-5

0 · Reply

LunarPixel87 Sep. 6 at 8:16 AM

$SANA Biotech indexes have been rallying quite hard, especially as interest rate cuts start coming into view. pretty much opposite of on fire. Sana has been noticeably absent from the rally, suggesting high degrees of shorting in the face of positive data and a more favorable funding environment for biotech on the horizon. I don't buy the cash burn narrative at all. CEO said just 2 days ago that they will have zero problem raising money for type 1 diabetes program from current investors. And as in my previous post, also thinks it likely they will find a partner for CAR-T program. Short interest has been high for well over a year. The shorts have been proven wrong by the human data all this year. There isn't a valid short thesis any more and those that are still short seem to be in denial and desperately trying to suppress the price. They're playing an awfully dangerous game. I suspect they're going to get burned very bad.

0 · Reply

LunarPixel87 Sep. 6 at 8:07 AM

$SANA found one of the shorts. It's not too expensive. Their immediate acquisition value based on their human data alone is worth many multiples more than 820M. Exponential increase in burn? No, I don't think you understand the meaning of exponential. There's a big difference between manufacturing for trials and scaling to meet customer demand. The whole reason they paused their internal manufacturing build and contracted out the work was to save money. Phase 1 starting mid 2026 is pure speculation and data deep 2027 is blatantly wrong. CEO literally just said they will move into patients very quickly post IND (e.g. within 1 month). First readout will likely be a month later like the UP421 trial. CEO says IND as early as 2026, that's all they've given us in regards to a date. CEO just said they are in talks with potential partners for the non-diabetes programs and said he thinks it's likely they will find one. Even said he's open to partner for diabetes if it's a very good deal.

2 · Reply

BioGem Sep. 6 at 6:10 AM

$SANA Despite its volatility I am holding my short here: -The basic outstanding shares including the recent dilution and prefunded warrants is 272M. At $3 this is 820M in market cap = too expensive. -While cash estimated in Sep is 140M and before year end in the 90M range, burn of $ will accelerate exponentially from here on (expensive manufacturing readiness). -Phase 1 won't start till mid 2026, and data not before deep 2027. -The value of the other products is null as they have no capital to proceed with them. -Biotech has been on fire, and at any pullback this dips faster. -Short interest is high = consensus of poor performance.

0 · Reply

LunarPixel87 Sep. 5 at 9:23 PM

$SANA mentioned in Cell again 10.1016/j.stem.2025.08.009 The Schrepfer team genetically modified peripheral blood T cells from a normal donor and infused a mixture of hypoimmune and non-engineered anti-CD19 CAR T cells into patients with B cell malignancies or with lupus nephropathy.8 The Schrepfer study, published in this issue of Cell Stem Cell, observed donor-specific T cell activation and DSA formation in the recipients due to the presence of unmodified cells in the infusion. Encouragingly, no T cell, antibody, or NK-cell targeting of the hypoimmune-engineered cells was detected in ex vivo assays. The Schrepfer team applied the same strategy to primary human pancreatic islets and showed evidence of graft survival without immunosuppression in a type 1 diabetes patient.9 Together, the safety and hints of immune avoidance of these hypoimmune-engineered cells point a path forward for overcoming the immune barrier through graft engineering. All need now is Science op ed., or ABC news :)

1 · Reply

BriOnH Sep. 5 at 8:53 PM

$SANA After watching Dr. Sonja’s presentation (link below), I’m curious what others think: Is there a possibility Dr. Sonja sees the future as growing organs in hypoimmune animals (pigs, NHP's, etc) as a better option than trying to overcome the problems of mass production of growing these cells, organs, from human islets? I didn't even realize until today she grew a fully hypoimmune mouse. Either way, it's clear that if she were to have stayed at Sana it most likely would have held her research back. That's not a knock against Sana, Sana has the primary focus of getting this to market, while her focus is expanding this to as far as it can go.

1 · Reply

Market Cap	808.54M
Revenue (ttm)	0.00
Net Income (ttm)	-266.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,002,300
Avg Vol	5,506,250
Day's Range	N/A - N/A
Shares Out	237.81M
Stochastic %K	70%
Beta	1.88
Analysts	Strong Sell
Price Target	$9.17